当商品の販売は、2011年07月19日を持ちまして終了しました。
Abstract
Genomics and Proteomics Research in Europe is Thriving
The European Union (EU) has become a popular hub for advanced research into genomics and
proteomics. This can be attributed to the significant government funding at both the national level
and from individual EU agencies. Moreover, Europe houses some of the largest pharmaceutical
companies that are extending their support to research programs related to genomics and proteomics,
either in-house or in collaboration with smaller firms. The primary goal is to go beyond the realms
of human genome sequencing and expand the list of identified proteins and genes, which will
ultimately aid in understanding disease mechanisms and developing corresponding therapeutics.
This Technical Insights research service analyses key developments in proteomics and genomics and
its impact on the field of drug discovery and development. In addition to evaluating research trends
in companies and universities in the EU, this study evaluates the important technology drivers and
challenges. Participants can use this research service to identify potential collaborators, stay
ahead of the competition and remain abreast of critical developments.
Genomics and Proteomics Gaining Prominence as Primary Tools for Drug Discovery
While the potential of genomics and proteomics is constantly growing, the most lucrative
applications lie in the field of drug discovery and development and molecular diagnostics.
Proteomics and genomics are expected to be key tools in target identification and validation and
ultimately expanding the list of cellular targets. "New information on the molecular mechanisms
responsible for disease has enhanced the identification and validation processes," says the
analyst of this research. "With regard to molecular diagnostics, the expectation is that
diseases with a genetic component can be treated according to specific genetic markers, medications
and dosages that are optimized for individual patients."
Human genomic research is accelerating as scientists seek effective therapies with the ability to
target the appropriate genes for activation inhibition or replacement. The target genes are
multiplying in numbers and researchers are hoping to develop treatments for a wide variety of
disorders, from cystic fibrosis to cancer and cardiovascular disease.
Enabling Technologies are Accelerating Progress in Genomics and Proteomics
Emerging technologies such as microarrays, automation and robotics are taking genomics and
proteomics research to new heights. "Weeks, if not months, were initially required to elucidate
the expression of a single gene," observes the analyst. "Now, tens and thousands of genes
can be studied in a single afternoon." In addition, previously time-consuming and
skill-intensive assays and preparations can now be accomplished thousands of samples at a time and
within a few hours. This is made possible through new computer-modelling approaches such as
molecular dynamics (MD), ligand docking (LD), pharmacophore modelling (PM), homology modelling (HM)
and enzyme-substrate modelling (ESM).
Since conventional technologies such as 2D gel electrophoresis pose certain limitations,
development of new technologies such as isotope coded affinity tags, 2D chromatographic separation,
terahertz pulsed imaging (TPI) and terahertz pulsed spectroscopy (TPS) and protein arrays are also
gaining importance.
Table of Contents
1 EXECUTIVE SUMMARY
Introduction
- Introduction
- Genomics
- Proteomics
- Primary Applications: Drug Discovery and Molecular Diagnostics
- Market Trends
Scope and Methodology
2 PRIMER ON GENOMICS AND PROTEOMICS TECHNOLOGIES
Genomics
- Introduction
- SNP Profiling
- Functional Genomics
- Structural Genomics
- Pharmacogenomics
- Toxicogenomics
- Chemical Genomics (Chemogenomics)
Proteomics
- Introduction
- Proteomics Techniques
Related Fields of Study
- Glycomics and Other "Omics"
- Systems Biology
3 APPLICATIONS ANALYSIS AND TRENDS
Genomics
- Drug Discovery
- Molecular Diagnostics
Proteomics
- Drug Discovery
- Molecular Diagnostics
- Antibodies as Therapeutics
4 NOTEWORTHY INNOVATION AT KEY ACADEMIC AND GOVERNMENT-RELATED INSTITUTIONS
Analysis and Ranking of Application Segments
- Introduction
- Regulatory Hurdles
Genomics
- DNA Chips
- Human Epigenome Project
Proteomics
- Protein Chips
- German Research Foundation To Establish Seven New Research Centers
5 NOTEWORTHY INNOVATION BY KEY COMPANIES
Genomics
- Pharmacogenomics
- Genome Sequencing
- Gene Expression
- Reverse Genomics
- Functional Genomics
- Applications
- Labeling and Detection Methods
- DNA Chips and Microarrays
- Chemical Genomics
- Additional Genomics Companies
Proteomics
- Protein Crystallography
- Spectroscopy
- Antibodies for Protein Identification; Auto-Immune Research
- Detection and Labeling
- Protein and Antibody Expression Systems
- Protein-Protein Interaction
- Protein chips
- Applications
- Additional Proteomics Companies
The Other ics
6 REGULATORY AND POLITICAL FACTORS
Government Guidelines and Support
- FDA Guidelines
- Governmental Support; Both Financial and IP Protection; Are Needed
Pharmaceutical Industry Response
- Pharmaceutical Industry Reluctance
- Fear of the New
7 INDUSTRY TRENDS
Market Trends
- Genomics
- Proteomics And Systems Biology
Enabling Technologies and Their Markets
- Electrophoresis and Proteome Informatics
- DNA and Protein Microarrays
- Spectroscopy and Chromatography
- Labs-on-a-Chip--Miniaturization Brings Higher Throughput with Less Sample
- Multiplexing and Biomarker-Based Diagnostics Market
- Automation
- New Tools for Genomics
- High-Throughput Screening Technologies Accelerate Drug Discovery
8 TECHNOLOGY ADOPTION FACTOR ANALYSIS
Technology Drivers
- Technology Features and Benefits
- Adoption Drivers for Genomics and Proteomics
- Analysis of Funding
Technology Restraints
- Technology or Product Development Restraints
- Competing Technologies and Complexity
9 CONTACTS AND PATENTS
Contacts
- European Companies
- Non-European Companies
Patents
- Patents--Section I
- Patents-- Section II
10 FROST & SULLIVAN 2005 SCIENCE AND TECHNOLOGY AWARDS
Technology Innovation
- Award Description
- Award Recipient
Technology Leadership
- Award Description
- Award Recipient
Product Leadership
- Award Description
- Award Recipient
11 DECISION SUPPORT DATABASE
Decision Support Database Relevant To This Study
- Government Healthcare Expenditure
- Private Healthcare Expenditure
- Total Healthcare Expenditure
- Government Biotech R&D Investments
- Private Biotech R&D Investments
- Pharma R&D Expenditure
